
Eli Lilly and Company LLY
Annual report 2025
added 02-12-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
897 M |
Market Cap[1] |
$ 935 B |
EBITDA (LTM) |
$ 2.37 B |
P/E (LTM) |
76.26 |
P/S (LTM) |
18.49 |
EPS (LTM) |
13.74 |
Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.
The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.
One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.
Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.
Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Amarin Corporation plc
AMRN
|
$ 14.81 | -0.34 % | $ 6.04 B | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Legend Biotech Corporation
LEGN
|
$ 17.8 | -1.44 % | $ 18.7 B | Nasdaq Global Select Market | ||
|
Anavex Life Sciences Corp.
AVXL
|
$ 3.93 | 0.26 % | $ 335 M | Nasdaq Capital Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Adagene
ADAG
|
$ 3.24 | 13.85 % | $ 182 M | Nasdaq Global Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
$ 0.79 | -7.27 % | $ 4.31 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.48 | -0.98 % | $ 8.37 B | Nasdaq Capital Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Biogen
BIIB
|
$ 195.63 | 0.06 % | $ 28.7 B | Nasdaq Global Select Market,SPB | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 216.28 | -0.83 % | $ 5 B | Nasdaq Global Select Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 60.51 | 1.12 % | $ 123 B | NYSE,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
BioNTech SE
BNTX
|
$ 106.24 | 0.45 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.41 | 1.81 % | $ 360 M | Nasdaq Global Select Market | ||
|
Burford Capital Limited
BUR
|
$ 9.33 | 0.32 % | $ 1.51 B | NYSE | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 14.8 | 1.13 % | $ 4.57 B | NYSE | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.